Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size.

ABSTRACT:

Background

Since December 2019, COVID-19 has spread to almost every corner of the world. In theory, tocilizumab and favipiravir are considered to be reliable drugs for the treatment of COVID-19 with elevated IL-6. We aimed to assess the efficacy and safety of tocilizumab combined with favipiravir in patients with COVID-19.

Methods

This was a multicenter trial in adults with COVID-19. Patients were randomly assigned (3:1:1) to a 14-day combination of favipiravir combined with tocilizumab (combination group), favipiravir, and tocilizumab. The primary outcome was the cumulative lung lesion remission rate (lung CT examination indicated absorption of lung inflammation).

Results

Between Feb 2 and March 15, 2020, 26 patients were recruited; 14 were randomly assigned to the c

SUBMITTER: Zhao H 

PROVIDER: S-EPMC7524677 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature